Law360, New York (April 7, 2017, 3:39 PM EDT) -- The Federal Circuit has recently foreclosed some appeals from the Patent Trial and Appeal Board and made the America Invents Act’s covered business method review program less potent. Here's a roundup of the court’s top rulings since January and their implications for intellectual property law.
Phigenix Inc. v. ImmunoGen Inc.
While the AIA says any party dissatisfied with a Patent Trial and Appeal Board decision can appeal, the Federal Circuit held in January that appellants must still comply with the constitutional requirements for bringing a case in an Article III court.
The court held that Phigenix had failed to demonstrate that there...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!